874 related articles for article (PubMed ID: 32554612)
41. An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.
Jemon K; Young V; Wilson M; McKee S; Ward V; Baird M; Young S; Hibma M
PLoS One; 2013; 8(6):e66866. PubMed ID: 23799135
[TBL] [Abstract][Full Text] [Related]
42. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
[TBL] [Abstract][Full Text] [Related]
43. Design and evaluation of a multi-epitope DNA vaccine against HPV16.
Zhu L; Cui X; Yan Z; Tao Y; Shi L; Zhang X; Yao Y; Shi L
Hum Vaccin Immunother; 2024 Dec; 20(1):2352908. PubMed ID: 38780076
[TBL] [Abstract][Full Text] [Related]
44. HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo.
Liao SJ; Deng DR; Zeng D; Zhang L; Hu XJ; Zhang WN; Li L; Jiang XF; Wang CY; Zhou JF; Wang SX; Zhang HW; Ma D
J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):735-742. PubMed ID: 24142729
[TBL] [Abstract][Full Text] [Related]
45. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
46. Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model.
Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
Life Sci; 2021 Nov; 285():119945. PubMed ID: 34516991
[TBL] [Abstract][Full Text] [Related]
47. Prevention and treatment of cervical cancer by a single administration of human papillomavirus peptide vaccine with CpG oligodeoxynucleotides as an adjuvant in vivo.
Yang Y; Che Y; Zhao Y; Wang X
Int Immunopharmacol; 2019 Apr; 69():279-288. PubMed ID: 30743204
[TBL] [Abstract][Full Text] [Related]
48. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.
Soong RS; Song L; Trieu J; Knoff J; He L; Tsai YC; Huh W; Chang YN; Cheng WF; Roden RB; Wu TC; Trimble CL; Hung CF
Clin Cancer Res; 2014 Nov; 20(21):5456-67. PubMed ID: 24893628
[TBL] [Abstract][Full Text] [Related]
49. Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines.
Lee SY; Oh JY; Kang TH; Shin HS; Cheng MA; Farmer E; Wu TC; Hung CF
J Biomed Sci; 2019 May; 26(1):41. PubMed ID: 31133013
[TBL] [Abstract][Full Text] [Related]
50. Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene.
Gao J; Fan L; Ma W; Xiao H
Microbiol Immunol; 2016 Sep; 60(9):626-33. PubMed ID: 27515281
[TBL] [Abstract][Full Text] [Related]
51. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model.
Ishida E; Lee J; Campbell JS; Chakravarty PD; Katori Y; Ogawa T; Johnson L; Mukhopadhyay A; Faquin WC; Lin DT; Wirth LJ; Pierce RH; Pai SI
Cancer Immunol Immunother; 2019 Aug; 68(8):1273-1286. PubMed ID: 31243491
[TBL] [Abstract][Full Text] [Related]
52. CD8
Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
[TBL] [Abstract][Full Text] [Related]
53. Customized Viral Immunotherapy for HPV-Associated Cancer.
Atherton MJ; Stephenson KB; Pol J; Wang F; Lefebvre C; Stojdl DF; Nikota JK; Dvorkin-Gheva A; Nguyen A; Chen L; Johnson-Obaseki S; Villeneuve PJ; Diallo JS; Dimitroulakos J; Wan Y; Lichty BD
Cancer Immunol Res; 2017 Oct; 5(10):847-859. PubMed ID: 28912369
[TBL] [Abstract][Full Text] [Related]
54. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
55. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
56. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout.
Zhen S; Lu J; Liu YH; Chen W; Li X
Cancer Gene Ther; 2020 Apr; 27(3-4):168-178. PubMed ID: 31455836
[TBL] [Abstract][Full Text] [Related]
57. Carboplatin/paclitaxel, E7-vaccination and intravaginal CpG as tri-therapy towards efficient regression of genital HPV16 tumors.
Domingos-Pereira S; Galliverti G; Hanahan D; Nardelli-Haefliger D
J Immunother Cancer; 2019 May; 7(1):122. PubMed ID: 31060612
[TBL] [Abstract][Full Text] [Related]
58. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.
Zeng Q; Peng S; Monie A; Yang M; Pang X; Hung CF; Wu TC
Hum Gene Ther; 2011 Jul; 22(7):809-19. PubMed ID: 21128743
[TBL] [Abstract][Full Text] [Related]
59. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
[TBL] [Abstract][Full Text] [Related]
60. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice.
Paz De la Rosa G; Monroy-García A; Mora-García Mde L; Peña CG; Hernández-Montes J; Weiss-Steider B; Gómez-Lim MA
Virol J; 2009 Jan; 6():2. PubMed ID: 19126233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]